Efficacy and safety of vildagliptin compared to placebo in patients with type 2 diabetes and mild hyperglycemia.

Next Previous
Trial Profile

Efficacy and safety of vildagliptin compared to placebo in patients with type 2 diabetes and mild hyperglycemia.

Completed
Phase of Trial: Phase III

Latest Information Update: 18 Feb 2015

At a glance

  • Drugs Vildagliptin (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Pharmacodynamics; Therapeutic Use
  • Sponsors Novartis

    • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 04 May 2012 Actual end date (May 2006) added as reported by ClinicalTrials.gov.
    • 05 Aug 2011 New source identifed and integrated (European Clinical Trials Database).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top